Targeting insulin-like growth factor type 1 receptor in cancer therapy.
It is believed that the insulin-like growth factor receptor type 1 (IGF-1R) signaling pathway plays a pivotal role in cancer growth, progression, and resistance to anticancer therapies. Strategies are being developed to block IGF-1R as an anticancer treatment. We reviewed several potential strategies for disrupting the IGF axis. We also reviewed the effects of two drugs that target the IGF-1R: monoclonal antibodies and tyrosine kinase inhibitors. Preliminary results of studies involving these agents provided a foundation for ongoing clinical trials, whose results in the near future will help us understand how to incorporate anti IGF-1R strategies into the current anticancer armamentarium.
Atzori
Francesco
F
Department of Medical Oncology, University of Cagliari, 09042, Cagliari, Italy. Francescoatzori74@yahoo.it
Traina
Tiffany A
TA
Ionta
Maria Teresa
MT
Massidda
Bruno
B
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D016503:Drug Delivery Systems; D004357:Drug Synergism; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage* / Q000627:therapeutic use; D017526:Receptor, IGF Type 1 / Q000037:antagonists & inhibitors*; D015398:Signal Transduction / Q000187:drug effects
D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D017526:Receptor, IGF Type 1